-
Management Board: Highlights of March 2019 meeting
Management Board: Highlights of March 2019 meeting
-
Management Board: Highlights of March 2019 meeting
Management Board: Highlights of March 2019 meeting
EMA’s Management Board re-elected Christa Wirthumer-Hoche as chair at its first meeting in the Agency’s new temporary premises, the SPARK building, in Amsterdam, Sloterdijk. The Board also heard updates on Brexit, medicines for children and the Clinical Trials Information System.
-
Management Board re-elects Christa Wirthumer-Hoche as chair
Management Board re-elects Christa Wirthumer-Hoche as chair
-
Management Board re-elects Christa Wirthumer-Hoche as chair
Management Board re-elects Christa Wirthumer-Hoche as chair
EMA’s Management Board today re-elected Christa Wirthumer-Hoche as its chair for a three-year mandate. This is Dr Wirthumer-Hoche’s second and final mandate as chair.
-
From lab to patient: the journey of a centrally authorised medicine
From lab to patient: the journey of a centrally authorised medicine
-
From lab to patient: the journey of a centrally authorised medicine
From lab to patient: the journey of a centrally authorised medicine
EMA has published a booklet describing the journey of a medicine for human use authorised through EMA, from initial research to discussions on patient access to medicines across the EU.
-
Updated guidance for industry on preparing for Brexit
Updated guidance for industry on preparing for Brexit
-
Updated guidance for industry on preparing for Brexit
Updated guidance for industry on preparing for Brexit
EMA and the European Commission provide additional information to help pharmaceutical companies prepare for the UK’s withdrawal from the EU.
